Elanco Animal Health is making progress on debt repayment, new product approvals, and launches. Learn why ELAN stock is a Buy ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

advancements in companion animal and livestock health; and diverse synthetic biology applications such as producing enzymes, biofuels and chemicals. Current licensees include GSK, Merck, Bayer ...

All the other companies, whether it was Eli Lilly, or Pfizer, or Novartis, Bayer - they have either ... of candidates and time to market or animal health products.” Indeed, there is no phase ...

Bayer AG is active in the German healthcare sector. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and animal health products.

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer argues PCB levels were safe ... and were also used in such products as carbonless copy paper, caulking, floor finish and paint. They were outlawed by the U.S. government in 1979 after ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

The glyphosate shortage that started the spring of 2021 is only intensifying as farmers prepare for the 2022 growing season. However, as growers try to source enough of the widely used herbicide ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...